TW202227499A - 識別ha-1抗原之結合蛋白及其用途 - Google Patents

識別ha-1抗原之結合蛋白及其用途 Download PDF

Info

Publication number
TW202227499A
TW202227499A TW110141526A TW110141526A TW202227499A TW 202227499 A TW202227499 A TW 202227499A TW 110141526 A TW110141526 A TW 110141526A TW 110141526 A TW110141526 A TW 110141526A TW 202227499 A TW202227499 A TW 202227499A
Authority
TW
Taiwan
Prior art keywords
cell
cells
tcr
binding protein
host cell
Prior art date
Application number
TW110141526A
Other languages
English (en)
Chinese (zh)
Inventor
利胡 那亞
蓋賓 麥克比思
索納爾 珍蓋爾威
茉莉 M 茱爾威茲
安德魯 S 巴辛斯基
許其開
安東尼 J 保朵特
多瑪茲 庫拉
Original Assignee
美商帝斯肯醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商帝斯肯醫療公司 filed Critical 美商帝斯肯醫療公司
Publication of TW202227499A publication Critical patent/TW202227499A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
TW110141526A 2020-11-06 2021-11-08 識別ha-1抗原之結合蛋白及其用途 TW202227499A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US63/110,851 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US63/111,462 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US63/129,804 2020-12-23
US202163175350P 2021-04-15 2021-04-15
US63/175,350 2021-04-15

Publications (1)

Publication Number Publication Date
TW202227499A true TW202227499A (zh) 2022-07-16

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110141526A TW202227499A (zh) 2020-11-06 2021-11-08 識別ha-1抗原之結合蛋白及其用途

Country Status (10)

Country Link
US (1) US20230398217A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240490A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549765A (cg-RX-API-DMAC7.html)
KR (1) KR20230117576A (cg-RX-API-DMAC7.html)
AU (3) AU2021323388C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197255A1 (cg-RX-API-DMAC7.html)
IL (1) IL302616A (cg-RX-API-DMAC7.html)
MX (1) MX2023005179A (cg-RX-API-DMAC7.html)
TW (1) TW202227499A (cg-RX-API-DMAC7.html)
WO (1) WO2022099100A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130009A1 (en) * 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2025217028A1 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2025217035A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
WO2025231299A1 (en) * 2024-05-02 2025-11-06 Fred Hutchinson Cancer Center Tcr t cell therapy targeting ha-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535199A (ja) * 2010-07-28 2013-09-12 イムノコア リミテッド T細胞レセプター
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
WO2020030631A1 (en) * 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
NL2021789B1 (en) * 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof

Also Published As

Publication number Publication date
IL302616A (en) 2023-07-01
JP2023549765A (ja) 2023-11-29
KR20230117576A (ko) 2023-08-08
AU2026200575A1 (en) 2026-02-19
CA3197255A1 (en) 2022-05-12
EP4240490A4 (en) 2025-06-18
WO2022099100A2 (en) 2022-05-12
MX2023005179A (es) 2023-07-13
AU2021323388B2 (en) 2022-07-28
WO2022099100A3 (en) 2022-06-16
US20230398217A1 (en) 2023-12-14
AU2021323388A1 (en) 2022-05-26
AU2022241563A1 (en) 2022-11-03
EP4240490A2 (en) 2023-09-13
AU2022241563B2 (en) 2025-11-27
AU2021323388C1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
AU2021323388C1 (en) Binding proteins recognizing HA-1 antigen and uses thereof
US20240197877A1 (en) Binding proteins recognizing ha-2 antigen and uses thereof
AU2022268347C1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
US20230272049A1 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
JP2024544903A5 (cg-RX-API-DMAC7.html)
TW202304964A (zh) Magec2免疫原性肽、識別magec2免疫原性肽之結合蛋白及其用途
KR20250080890A (ko) Prame 면역원성 펩티드, prame 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도
AU2025200025A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
AU2026202663A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN116940593A (zh) 识别ha-1抗原的结合蛋白及其用途
CN118103049A (zh) 识别ha-2抗原的结合蛋白及其用途
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途